The higher prevalence of FGFR alterations, including actionable FGFR2/3 alterations, in upper tract carcinomas compared to lower tract carcinomas shown in the current study is in concordance with findings from Sfakianos and colleagues.35 This group identified FGFR3 alterations in 35.6% of 83 upper tract carcinomas treated with nephroureterectomy and in 21.6% of 102 bladder carcinomas treated with radical cystectomy (P = .065). This evidence concerns the gene FGFR3 and urinary bladder carcinoma.